← Back to Analyst Consensus 
LXEO Buy
Lexeo Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 23, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 50% |
| Jun 25, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| May 11, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Jan 13, 2026 | Chardan Capital | maintain | Buy → Buy | $17 | 47% |
| Jan 13, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Dec 18, 2025 | Raymond James | initiate | — → Strong Buy | $25 | 54% |
| Dec 11, 2025 | Chardan Capital | maintain | Buy → Buy | $17 | 47% |
| Dec 1, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $19 | 50% |
| Nov 20, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $19 | 50% |
| Nov 5, 2025 | Chardan Capital | maintain | Buy → Buy | $17 | 47% |
| Oct 21, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| Oct 15, 2025 | Guggenheim | initiate | — → Buy | $30 | 52% |
| Oct 7, 2025 | Chardan Capital | maintain | Buy → Buy | $17 | 47% |
| Oct 7, 2025 | Leerink Partners | maintain | Outperform → Outperform | $20 | 50% |
| Oct 7, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $15 | 44% |
| Aug 15, 2025 | Chardan Capital | maintain | Buy → Buy | $15 | 47% |
| Aug 15, 2025 | Leerink Partners | maintain | Outperform → Outperform | $9 | 50% |
| Aug 15, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| Jul 31, 2025 | Oppenheimer | initiate | — → Outperform | $20 | 52% |
| May 30, 2025 | JP Morgan | maintain | Overweight → Overweight | $10 | 55% |
| May 16, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $15 | 44% |
| May 13, 2025 | Chardan Capital | maintain | Buy → Buy | $20 | 47% |
| May 12, 2025 | Leerink Partners | maintain | Outperform → Outperform | $16 | 50% |
| Apr 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Apr 8, 2025 | Chardan Capital | maintain | Buy → Buy | $22 | 47% |
| Mar 26, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Mar 25, 2025 | RBC Capital | maintain | Outperform → Outperform | $20 | 55% |
| Mar 25, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Mar 24, 2025 | Leerink Partners | maintain | Outperform → Outperform | $18 | 50% |
| Jan 21, 2025 | RBC Capital | reiterate | Outperform → Outperform | $24 | 55% |
| Nov 14, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $23 | 44% |
| Nov 13, 2024 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| Nov 13, 2024 | Leerink Partners | maintain | Outperform → Outperform | $19 | 50% |
| Oct 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Oct 30, 2024 | Chardan Capital | maintain | Buy → Buy | $23 | 47% |
| Oct 25, 2024 | Chardan Capital | maintain | Buy → Buy | $23 | 47% |
| Aug 14, 2024 | Chardan Capital | maintain | Buy → Buy | $23 | 47% |
| Aug 13, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $21 | 44% |
| Aug 13, 2024 | RBC Capital | reiterate | Outperform → Outperform | $24 | 55% |
| Jul 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $22 | 44% |
| Jul 15, 2024 | Chardan Capital | maintain | Buy → Buy | $23 | 47% |
| Jun 13, 2024 | Baird | initiate | — → Outperform | $28 | 55% |
| Jun 6, 2024 | HC Wainwright & Co. | initiate | — → Buy | $22 | 44% |
| Mar 12, 2024 | RBC Capital | maintain | Outperform → Outperform | $24 | 55% |
| Nov 28, 2023 | Chardan Capital | initiate | — → Buy | $23 | 47% |
| Nov 28, 2023 | Leerink Partners | initiate | — → Outperform | $19 | 50% |
| Nov 28, 2023 | RBC Capital | initiate | — → Outperform | $22 | 55% |
| Nov 28, 2023 | Stifel | initiate | — → Buy | $20 | 53% |
| Nov 28, 2023 | JP Morgan | initiate | — → Overweight | $20 | 55% |
Price Target Trend
Mar 30, 2026 Latest: $20.3 Oct 24, 2026
EPS Estimates
+1y $-1.37
Lo: $-1.74 Hi: $-1.15
8 analysts ▲1
+1q $-0.34
Lo: $-0.40 Hi: $-0.31
8 analysts ▲2
0y $-1.20
Lo: $-1.25 Hi: $-1.17
7 analysts ▲2
0q $-0.32
Lo: $-0.35 Hi: $-0.31
7 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days